Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion

The patent portfolio now includes 21 issued patents in North America, supporting the company's stated expansion strategy.

Rhea-AI Summary

Microbot Medical (MBOT) received a Canadian patent covering an adaptor that connects surgical tools to a motorized robotic surgical device.

The Canadian Intellectual Property Office grant brings its worldwide portfolio to 45 issued patents and 48 patent applications, including 21 issued patents in North America. The adaptor couples the proximal portion of tools such as guidewires and microcatheters to the robotic device. The company views patent protection as support for potential future market expansion and technology monetization, and says its portfolio gives it greater confidence to pursue regulatory clearances in additional markets beyond the U.S. and Israel.

Positive

• Minor pointCanadian patent granted for an adaptor connecting surgical tools to a motorized robotic surgical device.
• Minor pointGlobal portfolio now holds 45 issued patents, including 21 in North America.

Negative

• None.

Key Figures

Canadian patent granted: 1 patent Issued patents: 45 patents Patent applications: 48 applications +1 more

Canadian patent granted

1 patent

Adaptor for coupling a surgical tool to a motorized robotic surgical device

Issued patents

45 patents

Worldwide portfolio

Patent applications

48 applications

Worldwide portfolio

North American issued patents

21 patents

Included in the worldwide portfolio

Historical Context

1 past event · Latest: Oct 20

1 event

1. Oct 20

   Patent portfolio

   24h Move

   -0.6%

   Reported 44 issued patents and 49 applications while pursuing CE Mark for international expansion.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

guidewire, microcatheter, endovascular, fda-cleared

4 terms

guidewire medical

"guidewire, microcatheter and the like"

A guidewire is a thin, flexible metal wire used by doctors to steer catheters and other tools through blood vessels or body passages during minimally invasive medical procedures. For investors, guidewires matter because they are essential, often single-use components whose sales track procedure volume, hospital buying patterns, regulatory approvals, patent protection and liability exposure—similar to a small but critical part in a machine that drives steady, repeatable revenue for device makers.

microcatheter medical

"guidewire, microcatheter and the like"

A microcatheter is a very thin, flexible tube used by doctors to reach and treat small or hard‑to‑access blood vessels and body channels during minimally invasive procedures; it acts like a tiny guiding straw that lets physicians pass wires, deliver implants, contrast dye, or medicines precisely where needed. For investors, microcatheters matter because they are a core component of many interventional-device product lines, subject to clinical evidence, regulatory approval, and manufacturing scale—factors that affect market demand, pricing, and company revenue potential.

endovascular medical

"robotic system for peripheral endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

fda-cleared regulatory

"the only FDA-cleared, single-use, remotely operated robotic system"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, today announced that the Canadian Intellectual Property Office (CIPO) granted the Company a patent for an adaptor for coupling a proximal portion of an elongate surgical tool (guidewire, microcatheter and the like) to a motorized robotic surgical device. With this patent, the Company now holds 45 issued patents and 48 patent applications worldwide, including 21 issued patents in North America, as it continues to seek protection for the distinctive and unique characteristics of the LIBERTY^® System.

This patent reflects the Company's ongoing strategy to protect and maximize the value of its innovations through a growing global intellectual property portfolio. The Company believes that a strong patent estate is critical to supporting potential future market expansion and monetizing its novel technology.

“Our strategy to continue to strengthen our intellectual property portfolio in the U.S. and internationally is an important component to protecting and monetizing our technological innovation and gives us greater confidence to pursue regulatory clearances in additional markets, joining those in the U.S. and Israel,” commented Dr. Sarit Garten, Director of Intellectual Property.

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements relating to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, market acceptance of the LIBERTY system, the length and outcome of purchasing processes and the Company’s ability to convert sales leads into orders, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and the Company’s ability to obtain, maintain, protect and enforce its intellectual property rights, the scope and validity of such rights, and the risk of claims by third parties that the Company infringes their intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Microbot Medical's new Canadian patent cover?

The Canadian patent covers an adaptor for coupling the proximal portion of an elongate surgical tool, such as a guidewire or microcatheter, to a motorized robotic surgical device.

How many patents does Microbot Medical hold following the Canadian grant?

Microbot Medical holds 45 issued patents worldwide, including 21 issued patents in North America, and has 48 patent applications worldwide.